It was first approved in VHL disease, an inherited condition caused by mutations in VHL that result in ccRCC and other malignancies, and later for all ccRCC patients that have progressed after treatment with both an immune checkpoint and a vascular endothelial growth factor (VEGF) inhibitor [6,7]. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.